Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoav Lurie

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
World Journal of Gastroenterology|January 6, 2012
Constant serum levels of secreted asialoglycoprotein receptor sH2a and decrease with cirrhosisRon Benyair, Maria Kondratyev, Elena Veselkin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 14, 2005
Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infectionYoav Lurie, Regine Rouzier-Panis, George J M Webster, et al.
Plos One|November 19, 2011
A secreted form of the asialoglycoprotein receptor, sH2a, as a novel potential noninvasive marker for liver fibrosisElena Veselkin, Maria Kondratyev, Yoav Lurie, et al.
Antiviral Research|July 5, 2017
Modeling HCV cure after an ultra-short duration of therapy with direct acting agentsAshish Goyal, Yoav Lurie, Eric G Meissner, et al.
Journal of Gastroenterology and Hepatology|February 14, 2007
Acute hepatitis C in Israel: a predominantly iatrogenic disease?Yoav Lurie, Dan-Avi Landau, Laurence Blendis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 25, 2006
A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver diseaseShira Zelber-Sagi, Ada Kessler, Eli Brazowsky, et al.
Vaccine|February 4, 2006
Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccinePamela Rendi-Wagner, Daniel Shouval, Blaise Genton, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 6, 2006
Role of CYP2D6 polymorphism in predicting liver fibrosis progression rate in Caucasian patients with chronic hepatitis CSigal Fishman, Yoav Lurie, Hava Peretz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 25, 2014
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kineticsHarel Dahari, Shimon Shteingart, Inna Gafanovich, et al.
World Journal of Hepatology|July 27, 2016
Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case reportYaakov Hasin, Shimon Shteingart, Harel Dahari, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
World Journal of Gastroenterology|January 6, 2012
Constant serum levels of secreted asialoglycoprotein receptor sH2a and decrease with cirrhosisRon Benyair, Maria Kondratyev, Elena Veselkin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 14, 2005
Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infectionYoav Lurie, Regine Rouzier-Panis, George J M Webster, et al.
Plos One|November 19, 2011
A secreted form of the asialoglycoprotein receptor, sH2a, as a novel potential noninvasive marker for liver fibrosisElena Veselkin, Maria Kondratyev, Yoav Lurie, et al.
Antiviral Research|July 5, 2017
Modeling HCV cure after an ultra-short duration of therapy with direct acting agentsAshish Goyal, Yoav Lurie, Eric G Meissner, et al.
Journal of Gastroenterology and Hepatology|February 14, 2007
Acute hepatitis C in Israel: a predominantly iatrogenic disease?Yoav Lurie, Dan-Avi Landau, Laurence Blendis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 25, 2006
A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver diseaseShira Zelber-Sagi, Ada Kessler, Eli Brazowsky, et al.
Vaccine|February 4, 2006
Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccinePamela Rendi-Wagner, Daniel Shouval, Blaise Genton, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 6, 2006
Role of CYP2D6 polymorphism in predicting liver fibrosis progression rate in Caucasian patients with chronic hepatitis CSigal Fishman, Yoav Lurie, Hava Peretz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 25, 2014
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kineticsHarel Dahari, Shimon Shteingart, Inna Gafanovich, et al.
World Journal of Hepatology|July 27, 2016
Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case reportYaakov Hasin, Shimon Shteingart, Harel Dahari, et al.
Pageof 4